John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.
As I write this column, I am attending the 64th American Society of Hematology (ASH) Annual Meeting and Exposition. As is always the case, there are more big stories of amazing progress in the field of hematology and oncology than I can possibly summarize in one short column. One of these, which I have written about before and will probably write about again, is the emergence of bispecific antibodies to redirect native T lymphocytes against malignant B lymphocytes. But in this column I’ll focus on a different and perhaps equally important story—namely, that measurement of circulating tumor DNA (ctDNA) can be used to predict outcomes and assess responses to treatment of various lymphomas.
Detection of microscopic amounts of measurable residual disease (MRD) is not entirely a new story in hematology. At this ASH meeting, we are now seeing firm evidence that MRD testing with novel technologies can be used in a variety of ways in lymphomas. First, higher baseline levels of ctDNA correlate with adverse outcomes in patients with both aggressive non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma. Second, failure of MRD to become undetectable during and after therapy for aggressive NHL, mantle cell lymphoma, and Hodgkin lymphoma predicts a higher likelihood of recurrence. Third, when used at the end of treatment in aggressive lymphoma, a specific test used to measure ctDNA called PhasED-Seq was superior to PET/CT scans, the conventional method of assessing response to therapy in aggressive lymphomas, at predicting which patients would and would not relapse.
One can imagine using MRD results during treatment to tailor therapy for individual patients. Can patients who achieve undetectable MRD during therapy have their therapy shortened or reduced? Should patients who do not achieve undetectable MRD during or after therapy have their therapy intensified? Can we omit scans in patients whose MRD tests become negative after therapy, thereby reducing cost and exposure to potentially harmful radiation? I would advise that we not jump to conclusions and think we know the answers to these questions without controlled clinical trials. For example, in a mantle cell lymphoma study, patients with undetectable MRD still benefited from maintenance rituximab (Rituxan) as opposed to stopping treatment. Not all MRD tests are created equal, so the characteristics of the tests will need to be considered when designing trials to act on MRD results.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More